Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is reporting on its capital and upcoming clinical milestones. As part of the report, the company noted it has C$70M in potential funding raised through a combination of a common share purchase agreement … Continue reading InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Report on Status of Capital, Product Development